XML 18 R7.htm IDEA: XBRL DOCUMENT v3.23.1
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
2 Months Ended 3 Months Ended
Mar. 31, 2022
Mar. 31, 2023
Cash flows from operating activities    
Net loss before redeemable noncontrolling interest $ (7,819) $ (9,795)
Adjustments to reconcile net loss to net cash used in operating activities:    
Anti-dilution share issuance compensation   2,186
Share-based compensation   180
Research and development acquired license 7,500  
Change in fair value of share-based payment liability   1,854
Change in fair value of note payable   2,244
Change in fair value of private placement warrants   (177)
Foreign exchange transaction loss   9
Changes in operating assets and liabilities:    
Prepaid expenses and other current assets   (213)
Accounts payable and accrued expenses 39 455
Net cash used in operating activities (280) (3,257)
Cash flows from investing activities    
Purchase of research and development license (5,000)  
Net cash used in investing activities (5,000)  
Cash flows from financing activities    
Proceeds from issuance of Series A-1 convertible preferred shares 10,000  
Settlement of note payable   (10,000)
Proceeds from issuance of Class A Ordinary Shares upon Closing of Business Combination   56,683
Payment of deferred transaction costs   (1,030)
Net cash provided by financing activities 10,000 45,653
Net increase in cash 4,720 42,396
Cash, beginning of period   1,567
Cash, end of period 4,720 43,963
Supplemental Disclosure of Non-Cash Investing and Financing Activities    
Issuance of Series A-1 convertible preferred shares for license $ 2,500  
Conversion of Series A-1 convertible preferred shares for Class A Ordinary Shares   14,686
Assumption of public and private placement warrants in connection with Business Combination   3,715
Reclassification of public warrant liability to equity   2,001
Settlement of research and development license consideration liability   4,488
Transaction costs include in accounts payable   154
Reclassification of deferred transaction costs to additional paid-in capital   $ 4,015